Le Lézard27m
Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for the Treatment of IgA Nephropathy in Adults
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the decision to submit a Biologics License Application (BLA) in the U.S. for ...
BioSpace1h
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
Medscape3h
FDA Considers New Dupilumab Data for Chronic Spontaneous Urticaria Indication
The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
HCW Biologics Shares Surge on License Agreement
HCW Biologics shares skyrocketed as the company entered a licensing agreement with China's WY Biotech for an immunotherapeutic product candidate.
Broward pharma developer inks $7 million deal with Chinese firm
The deal is focused on a preclinical molecule that could potentially be used to treat age-related illnesses, such as cancer.